-
2
-
-
84923190501
-
Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies
-
O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16(1):1–12.
-
(2015)
Obes Rev
, vol.16
, Issue.1
, pp. 1-12
-
-
O’Neill, S.1
O’Driscoll, L.2
-
3
-
-
84929501636
-
Prevalence of the metabolic syndrome in the United States, 2003–2012
-
Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015; 313(19):1973–1974.
-
(2015)
JAMA
, vol.313
, Issue.19
, pp. 1973-1974
-
-
Aguilar, M.1
Bhuket, T.2
Torres, S.3
Liu, B.4
Wong, R.J.5
-
4
-
-
84893193652
-
The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: A collaborative analysis of ten large cohort studies
-
van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.
-
(2014)
BMC Endocr Disord
, vol.14
, pp. 9
-
-
Van Vliet-Ostaptchouk, J.V.1
Nuotio, M.L.2
Slagter, S.N.3
-
5
-
-
84958921233
-
Canagliflozin: A sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
-
Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358(1):28–43.
-
(2015)
Ann N Y Acad Sci
, vol.1358
, Issue.1
, pp. 28-43
-
-
Rosenthal, N.1
Meininger, G.2
Ways, K.3
-
6
-
-
84874291673
-
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
-
Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382.
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.4
, pp. 372-382
-
-
Stenlöf, K.1
Cefalu, W.T.2
Kim, K.A.3
-
7
-
-
84893299467
-
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATAM study
-
Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATAM study. Curr Med Res Opin. 2014;30(2):163–175.
-
(2014)
Curr Med Res Opin
, vol.30
, Issue.2
, pp. 163-175
-
-
Stenlöf, K.1
Cefalu, W.T.2
Kim, K.A.3
-
8
-
-
84887997289
-
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial
-
Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582–2592.
-
(2013)
Diabetologia
, vol.56
, Issue.12
, pp. 2582-2592
-
-
Lavalle-González, F.J.1
Januszewicz, A.2
Davidson, J.3
-
9
-
-
84888059660
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial
-
Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267–1282.
-
(2013)
Int J Clin Pract
, vol.67
, Issue.12
, pp. 1267-1282
-
-
Wilding, J.P.1
Charpentier, G.2
Hollander, P.3
-
10
-
-
84898791440
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
-
Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014; 16(5):467–477.
-
(2014)
Diabetes Obes Metab
, vol.16
, Issue.5
, pp. 467-477
-
-
Forst, T.1
Guthrie, R.2
Goldenberg, R.3
-
11
-
-
84930844091
-
Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes
-
Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403–411.
-
(2015)
Diabetes Care
, vol.38
, Issue.3
, pp. 403-411
-
-
Neal, B.1
Perkovic, V.2
De Zeeuw, D.3
-
12
-
-
84942320701
-
Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: A randomized, controlled trial
-
Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther. 2015;6(3):289–302.
-
(2015)
Diabetes Ther
, vol.6
, Issue.3
, pp. 289-302
-
-
Fulcher, G.1
Matthews, D.R.2
Perkovic, V.3
-
13
-
-
84955184453
-
Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
-
Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(1):82–91.
-
(2016)
Diabetes Obes Metab
, vol.18
, Issue.1
, pp. 82-91
-
-
Fulcher, G.1
Matthews, D.R.2
Perkovic, V.3
-
14
-
-
84962069581
-
Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy in drug-naive type 2 diabetes
-
Rosenstock J, Chuck L, Gonzalez-Ortiz M, Merton K, Craig J, Capuano G. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy in drug-naive type 2 diabetes. Diabetes Care. 2016;39(3):353–362.
-
(2016)
Diabetes Care
, vol.39
, Issue.3
, pp. 353-362
-
-
Rosenstock, J.1
Chuck, L.2
Gonzalez-Ortiz, M.3
Merton, K.4
Craig, J.5
Capuano, G.6
-
15
-
-
84973549996
-
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
-
Rodbard HW, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18(8):812–819.
-
(2016)
Diabetes Obes Metab
, vol.18
, Issue.8
, pp. 812-819
-
-
Rodbard, H.W.1
Seufert, J.2
Aggarwal, N.3
-
16
-
-
84876311251
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
-
Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–473.
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.5
, pp. 463-473
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
-
17
-
-
84912527805
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
-
Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016–1027.
-
(2014)
Diabetes Obes Metab
, vol.16
, Issue.10
, pp. 1016-1027
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
-
18
-
-
84880543926
-
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial
-
Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 2013;41(2):72–84.
-
(2013)
Hosp Pract
, vol.41
, Issue.2
, pp. 72-84
-
-
Bode, B.1
Stenlöf, K.2
Sullivan, D.3
Fung, A.4
Usiskin, K.5
-
19
-
-
84964240560
-
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes
-
Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294–303.
-
(2015)
Diabetes Obes Metab
, vol.17
, Issue.3
, pp. 294-303
-
-
Bode, B.1
Stenlöf, K.2
Harris, S.3
-
20
-
-
84884167643
-
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
-
Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382(9896):941–950.
-
(2013)
Lancet
, vol.382
, Issue.9896
, pp. 941-950
-
-
Cefalu, W.T.1
Leiter, L.A.2
Yoon, K.H.3
-
21
-
-
84940110139
-
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study
-
Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3): 355–364.
-
(2015)
Diabetes Care
, vol.38
, Issue.3
, pp. 355-364
-
-
Leiter, L.A.1
Yoon, K.H.2
Arias, P.3
-
22
-
-
84891784200
-
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week, randomized trial
-
Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care. 2013;36(9):2508–2515.
-
(2013)
Diabetes Care
, vol.36
, Issue.9
, pp. 2508-2515
-
-
Schernthaner, G.1
Gross, J.L.2
Rosenstock, J.3
-
23
-
-
84919491900
-
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
-
Ji L, Han P, Liu Y, et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab. 2015;17(1):23–31.
-
(2015)
Diabetes Obes Metab
, vol.17
, Issue.1
, pp. 23-31
-
-
Ji, L.1
Han, P.2
Liu, Y.3
-
24
-
-
84959194078
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America
-
Lavalle-González FJ, Eliaschewitz FG, Cerdas S, Del Pilar CM, Tong C, Alba M. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Curr Med Res Opin. 2016; 32(3):427–439.
-
(2016)
Curr Med Res Opin
, vol.32
, Issue.3
, pp. 427-439
-
-
Lavalle-González, F.J.1
Eliaschewitz, F.G.2
Cerdas, S.3
Del Pilar, C.M.4
Tong, C.5
Alba, M.6
-
25
-
-
84957709696
-
Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside
-
Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38(12):2344–2353.
-
(2015)
Diabetes Care
, vol.38
, Issue.12
, pp. 2344-2353
-
-
Mudaliar, S.1
Polidori, D.2
Zambrowicz, B.3
Henry, R.R.4
-
26
-
-
84919999219
-
Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1):140–149.
-
(2015)
Diabetes Care
, vol.38
, Issue.1
, pp. 140-149
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
27
-
-
84899960517
-
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: A pooled analysis of clinical studies
-
Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014; 14(1):37.
-
(2014)
BMC Endocr Disord
, vol.14
, Issue.1
, pp. 37
-
-
Sinclair, A.1
Bode, B.2
Harris, S.3
-
28
-
-
84961833550
-
Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: A pooled analysis
-
Sinclair AJ, Bode B, Harris S, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc. 2016;64(3):543–552.
-
(2016)
J am Geriatr Soc
, vol.64
, Issue.3
, pp. 543-552
-
-
Sinclair, A.J.1
Bode, B.2
Harris, S.3
-
29
-
-
84977071302
-
Impact of age and estimated glomerular filtration rate on the glycaemic efficacy and safety of canagliflozin: A pooled analysis of clinical studies
-
Gilbert RE, Weir MW, Fioretto P, et al. Impact of age and estimated glomerular filtration rate on the glycaemic efficacy and safety of canagliflozin: a pooled analysis of clinical studies. Can J Diabetes. 2016;40(3): 247–257.
-
(2016)
Can J Diabetes
, vol.40
, Issue.3
, pp. 247-257
-
-
Gilbert, R.E.1
Weir, M.W.2
Fioretto, P.3
-
30
-
-
84940775310
-
The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus
-
Gavin JR III, Davies MJ, Davies M, Vijapurkar U, Alba M, Meininger G. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(9):1693–1702.
-
(2015)
Curr Med Res Opin
, vol.31
, Issue.9
, pp. 1693-1702
-
-
Gavin, J.R.1
Davies, M.J.2
Davies, M.3
Vijapurkar, U.4
Alba, M.5
Meininger, G.6
-
31
-
-
84964986253
-
Efficacy and safety of canagliflozin in type 2 diabetes patients of different ethnicity
-
Davidson JA, Aguilar R, Lavalle González FJ, et al. Efficacy and safety of canagliflozin in type 2 diabetes patients of different ethnicity. Ethn Dis. 2016;26(2):221–228.
-
(2016)
Ethn Dis
, vol.26
, Issue.2
, pp. 221-228
-
-
Davidson, J.A.1
Aguilar, R.2
Lavalle González, F.J.3
-
32
-
-
84925345083
-
Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus
-
Wilding JPH, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications. 2015;29(3):438–444.
-
(2015)
J Diabetes Complications
, vol.29
, Issue.3
, pp. 438-444
-
-
Wilding, J.1
Blonde, L.2
Leiter, L.A.3
-
33
-
-
84961223678
-
Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
-
Rahman A, Kittikulsuth W, Fujisawa Y, et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens. 2016;34(5):893–906.
-
(2016)
J Hypertens
, vol.34
, Issue.5
, pp. 893-906
-
-
Rahman, A.1
Kittikulsuth, W.2
Fujisawa, Y.3
-
34
-
-
84885476895
-
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
-
Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1–3):246–255.
-
(2013)
Eur J Pharmacol
, vol.715
, Issue.1-3
, pp. 246-255
-
-
Tahara, A.1
Kurosaki, E.2
Yokono, M.3
-
35
-
-
83655167071
-
Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
-
Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012;14(1):94–96.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.1
, pp. 94-96
-
-
Thomas, L.1
Grempler, R.2
Eckhardt, M.3
-
36
-
-
34548500797
-
Challenges in developing therapies for the metabolic syndrome
-
Matfin G. Challenges in developing therapies for the metabolic syndrome. Br J Diabetes Vasc Dis. 2007;7(4):152–156.
-
(2007)
Br J Diabetes Vasc Dis
, vol.7
, Issue.4
, pp. 152-156
-
-
Matfin, G.1
-
37
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22):2117–2128.
-
(2015)
N Engl J Med
, vol.373
, Issue.22
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
|